UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

N/ANot Yet RecruitingNCT06895681

University of California, San Francisco50,000 enrolled

Overview

This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.

Primary Objective: 1. To generate a repository of participant-derived tumor models\* and specimens\*\* - annotated with demographic, clinical, and pathologic data - from adults with solid tumor malignancies with germline or somatic tumor-associated mutations and/or a personal or family history of cancer. * Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs). * Specimens may include tissue, ascites and pleural fluid, and blood. Exploratory Objectives 1. To correlate in vivo drug sensitivity of participant-derived models with patient clinical response. 2. To conduct blood-based assessment of tumor-associated biomarkers (DNA/RNA/protein, etc.). 3. To describe tumor and blood-based biomarkers that are predictive of clinical response. 4. To correlate changes in tumor and blood-based biomarker expression with clinical outcomes over time. 5. To perform genomic and transcriptomic profiling of banked specimens and correlate findings with clinical outcomes, prognostic markers, and biomarkers. 6. Unspecified cancer-centric research in the Munster Lab and other future unspecified research. OUTLINE: Participants will have biospecimens collected at non-study, routine procedures or visits to be stored at UCSF. Specimens will be processed and banked as per standard operating procedure. Participants will be followed through medical record chart review for a period of 10 years after signing informed consent, and be contacted every 3 months (± 2 months) for the first year and every 6 months (± 3 months) thereafter to allow updates to health status.

Study Type

OBSERVATIONAL

Enrollment

50,000

Conditions

Solid Tumor

Interventions

Blood SamplePROCEDURE

Obtained at the time of non-study related routine blood draw.

Tissue SamplePROCEDURE

Obtained at the time of non-study related routine biopsy or surgical procedure.

Excess fluid SamplePROCEDURE

Obtained at the time of non-study related routine biopsy, surgical procedure, paracentesis, or thoracentesis procedure.

Medical Chart ReviewOTHER

Demographic, clinical, and pathologic information will be extracted from the medical record

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: For participants undergoing collection of tissue, ascites, and/or pleural effusions: 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted. 2. Individuals 18 years of age or older on the day of signing informed consent. 3. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and/or Individuals with a family history or personal history of cancer. 4. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol): 1. Surgical resection 2. Biopsy (open, incisional, excisional, punch, core needle, and/or fine needle aspiration (FNA) are all permitted) 3. Paracentesis 4. Thoracentesis For participants undergoing blood banking: 1. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted. 2. Individuals 18 years of age or older on the day of signing informed consent. 3. Individuals with a family history or personal history of cancer. 4. Must be planning to undergo a blood draw as part of their routine care (or as a research procedure under a University of California, San Francisco (UCSF) -sponsored investigator-initiated trial (IIT) protocol); or willing to undergo an additional blood draw outside of their routine care. Exclusion Criteria: 1\. Known history of HIV, Hepatitis B, or Hepatitis C (as documented in the medical record) or other infectious disease that in the judgment of the investigator could pose a risk to research personnel or mice, or negatively impact Patient derived xenografts (PDX) tumor engraftment.

Outcomes

Primary Outcomes

Develop participant-derived tumor models of hereditary cancers

Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs). These models recapitulate the biology and tissue context of the original tumors from which they are derived and can be used to study effective therapeutic strategies.

Time frame: Up to 10 years